Duluth, Ga., and Pittsboro, N.C. - Biolex Therapeutics, Inc and Merial Ltd today announced that they have entered into a new, broad-ranging research and development collaboration to produce innovative ...

Octoplus will provide manufacturing and process development services and stands to earn $138 million in milestones. Biolex Therapeutics is paying OctoPlus $11 million for its 50% share of commercial ...

PITTSBORO, N.C., April 27 (UPI) -- Biolex said Locteron, a potential hepatitis C treatment, appeared safe in a phase 1 trial involving healthy volunteers. Biolex said phase 2 trials of Locteron, which ...

Biolex Therapeutics is calling it quits after burning through $190 million of venture cash from a slate of top-tier biopharma players on a once-promising hepatitis C drug. In its heyday the Pittsboro, ...

Biolex Therapeutics has announced three new additions to its management team. Each of these pharmaceutical executives brings a proven track record in the development and commercialization of ...

PITTSBORO, NORTH CAROLINA, November 28, 2006 - Biolex Therapeutics today announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX SystemSM to produce ...

Biolex Therapeutics, a Triangle-based biotechnology company, said Monday it has raised $60 million in new funding from private investors – an amount believed to be one of the largest rounds of venture ...

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Prior to <a href="http://www.bizjournals.com/triangle/blog ...

Pittsboro-based Biolex has named Bipin Dalmia vice president of business development. Dalmia joins Biolex from Syngenta Plant Science, where he served as business unit leader for Syngenta's ...

With an alternative way of producing proteins from plants as a selling point, Biolex Inc. raised $24 million in its latest private round, which it hopes will be its last. "We had three previous rounds ...